Alexion Pharmaceuticals Australasia

22 PBAC submissions on file, active 2008–2025. 68% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Ravulizumab
  Neurology · Recommended with restriction · 2025$73M
• Eculizumab
  Neurology · Recommended with restriction · 2021—
• Asfotase alfa rch
  Rare disease · Noted · 2018—
• Selumetinib
  Rare disease · Recommended with restriction · 2024—
• Sebelipase alfa
  Metabolic · Recommended with restriction · 2022—

Therapy area mix

Activity by year

2008 (1) · 2009 (1) · 2010 (1) · 2013 (1) · 2014 (2) · 2017 (2) · 2018 (2) · 2020 (2) · 2021 (2) · 2022 (2) · 2023 (2) · 2024 (3) · 2025 (1)

Rejection patterns

Across 7 Not recommended decisions on file.

• 1×Heterogeneity of eligible population introduces significant uncertainty in magnitude of benefit
• 1×reliance on secondary outcomes with non-significant changes in primary outcome (6MWT distance and quality of life)
• 1×uncertain utilities based on clinical expert opinion
• 1×uncertain costs due to self-administration assumptions
• 1×complex proposed restriction requiring further modification